Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.36 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.36 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.36 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.35 |
| ▸ | FUT5 | Q11128 | 1/20 | 0.35 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.34 |
| ▸ | TERT | O14746 | 1/20 | 0.34 |
| ▸ | KRAS | P01116 | 1/20 | 0.33 |
| ▸ | F2 | P00734 | 1/20 | 0.33 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.33 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5908163 | 0.91 | TERT (0.35) | POLBP2RY2P2RY4P2RY6P2RY1 | |
| SCHEMBL5908148 | 0.91 | POLB (0.35) | POLBP2RY2P2RY4P2RY6P2RY1 | |
| SCHEMBL5694292 | 0.84 | IMPDH2 (0.39) | FUT5IMPDH2KRASTAS1R3TAS1R1 | |
| SCHEMBL5694286 | 0.82 | IMPDH2 (0.36) | FUT5IMPDH2KRASTAS1R3TAS1R1 | |
| SCHEMBL5908152 | 0.82 | TAS1R3 (0.34) | POLBP2RY2P2RY4P2RY6P2RY1 | |
| SCHEMBL5694206 | 0.77 | P2RY12 (0.36) | P2RY2P2RY6P2RY1IMPDH2KRAS | |
| SCHEMBL5694326 | 0.77 | P2RY6 (0.37) | P2RY2P2RY4P2RY6IMPDH2KRAS | |
| SCHEMBL5694266 | 0.75 | P2RY12 (0.35) | P2RY2P2RY6P2RY1IMPDH2KRAS | |
| SCHEMBL5694309 | 0.75 | P2RY6 (0.35) | P2RY2P2RY4P2RY6IMPDH2KRAS | |
| SCHEMBL5694137 | 0.72 | IMPDH2 (0.38) | FUT5IMPDH2KRASTAS1R3TAS1R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060167241-A1 | Method for synthesizing cyclic bisdinucleoside | MITSUI CHEMICALS, INC. (JP) | 2006-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060167241-A1 | Method for synthesizing cyclic bisdinucleoside | NSUN2, POLR2H, POLB | POLB 3/4885P2RY2 3700/4885P2RY4 4394/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.